Key result
In obese patients undergoing bariatric surgery, a 4-g dose of cefoxitin provided inadequate coverage, achieving the PK/PD target in only 37.3% of patients for S. aureus and 0% for anaerobic bacteria.
Why the study?
The optimal dose of cefoxitin for antibiotic prophylaxis in obese patients remains uncertain.
Does a 4-g dose of cefoxitin provide adequate PK/PD target attainment in obese patients undergoing bariatric surgery?
Observational (n=200)
No
Does a 4-g dose of cefoxitin provide adequate PK/PD target attainment in obese patients undergoing bariatric surgery?
In obese patients undergoing bariatric surgery, a 4-g dose of cefoxitin leads to inadequate PK/PD target attainment for most common pathogens, particularly with longer surgery duration and BMI ≥50 kg/m2.
Answers are grounded in this paper and cite their sources.
Suggests caution with 4-g cefoxitin prophylaxis in obese bariatric patients; leaves open optimal dosing pending randomized trials.
BACKGROUND: The optimal dose of cefoxitin for antibiotic prophylaxis in obese patients remains uncertain. We evaluated the adequacy of a 4-gram dosing regimen of cefoxitin against the most frequent pathogens that infect patients undergoing bariatric surgery. The secondary outcomes were the factors related to underdosage. RESULTS: ) were associated with reaching the target concentrations. CONCLUSIONS: increase the risk of underdosage.
No takes yet. Share an insight, caveat, or question.
Belveyre et al. (2019) conducted an observational in Obesity requiring bariatric surgery (n=200). Cefoxitin was evaluated on Percentage of patients who met the PK/PD target (100% fT>4×MIC) of cefoxitin from incision to wound closure. In obese patients undergoing bariatric surgery, a 4-g dose of cefoxitin provided inadequate coverage, achieving the PK/PD target in only 37.3% of patients for S. aureus and 0% for anaerobic bacteria.
Synapse has enriched 10 related papers. Consider them for comparative context: